Issue link: http://www.e-digitaleditions.com/i/552614
New 'Quality Solutions for Inhaler Testing (2015 Edition)' Request your copy now! USA, Canada & Mexico: MSP Corporation 5910 Rice Creek Parkway Suite 300, Shoreview Minnesota 55126 USA Tel: +1 651 287 8100 Fax: +1 651 287 8140 e-mail: sales@mspcorp.com web site: www.mspcorp.com Austria, France, Germany, Italy & Switzerland: Copley Scientific AG Erlenstrasse 27 Postfach 152 CH-4106 Therwil Switzerland Tel: +41 (0)61 725 25 35 Fax: +41 (0)61 721 31 87 e-mail: sales@copleyscientific.ch web site: www.copleyscientific.com UK, Ireland & International Sales: Copley Scientific Limited Colwick Quays Business Park Private Road No. 2, Colwick Nottingham NG4 2JY United Kingdom Tel: +44 (0)115 961 6229 Fax: +44 (0)115 961 7637 e-mail: sales@copleyscientific.co.uk web site: www.copleyscientific.com S C I E N T I F I C '340)= '340)= Copley Scientific's new brochure provides a 'go to' reference for the development of optimal in vitro testing strategies for characterising orally inhaled and nasal drug products (OINDPs). A distillation of the company's globally recognised expertise, it incorporates simple, easy-to-understand information on the regulatory requirements and pharmacopeia methods for both innovator and generic inhaler testing. Presentation of the company's extensive range of inhaler testing equipment is complemented by detailed guidance on how to use each product to efficiently gather essential data. Copley Scientific is the world's leading manufacturer of inhaler testing equipment and has an established track record of introducing new products to meet evolving OINDP testing requirements. 'Quality Solutions for Inhaler Testing (2015 Edition)' is the latest, substantially expanded version of the company's widely referenced brochure, with new introductions reflecting current trends in the field. Products making their debut include: accessories specifically for the testing of generic Fluticasone Propionate (FP) and Salmeterol; equipment for testing metered dose inhalers (MDIs) with add-on devices in accordance with a recently released draft US Pharmacopeia (USP) chapter; and new ancillaries for enhancing the productivity of cascade impaction testing. S C I E N T I F I C '340)= '340)= /,"-Ê ,-ÊÊÊÊUÊÊÊÊ,9Ê*"7,Ê ,-ÊÊÊÊUÊÊÊÊ 1-,-ÊÊÊÊUÊÊÊÊ -Ê-*,9-ÊÊ Q u a l i t y S o l u t i o n s f o r I n h a l e r Te s t i n g Ê Ê Ê 2 0 1 5 E D I T I O N